Fundraising Fox
/Companies
Sign in

Arch Therapeutics

Wellesley, US · Founded 2009 · Nevada corporation

Find your way into Arch Therapeutics

Sign up to see every warm intro you have to Arch Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Arch Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Arch Therapeutics develops the AC5 Advanced Wound System, a wound care product available in the USA for both government and non-government purchasers. The company operates in the medical device sector focused on wound management.

BiotechMedical Devices

Founders & leadership

Arch Therapeutics was founded in 2009 by Terrence Norchi.

TNTerrence Norchi
Terrence NorchiFounderTerrence Norchi is a physician and CEO of Arch Therapeutics, which he co-founded based on MIT-licensed intellectual property to develop self-assembling peptide technology for wound care; he previously managed a $4 billion healthcare mutual fund.
WCWilliam Cotter
William CotterChief Operating Officer (COO) - July 2013 to July 20152012–2015He has held senior leadership roles in product development, operations, quality and regulatory affairs, and strategic partnerships across the medical devices, diagnostics, and biologics sectors.
RD
Richard DavisExecutive
AB
Alan BarberExecutive

Board

AD
Avtar DhillonBoard director
AR
Arthur RosenthalBoard director

Reported raises · per SEC filings

Form D private placements

$18.7M disclosed across 6 rounds · 2014–2022

▶$4.2MraisedJul 2022 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Guy FishDirector
  • Laurence HicksDirector
  • Daniel M. YrigoyenExecutive Officer
  • Terrence W. NorchiExecutive Officer, Director
  • Punit DhillonDirector
  • Michael S. AbramsExecutive Officer
Offering amount
$4.2M
Amount sold
$4.2M
Sales commissions
$240K
Placement agents
Maxim Group LLP
First sale
Jul 2022
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.9MraisedFeb 2021 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terrence W. NorchiExecutive Officer, Director
  • Richard E. DavisExecutive Officer
  • James R. SulatDirector
  • Punit DhillonDirector
Offering amount
$7.5M
Amount sold
$6.9M
Sales commissions
$492.8K
Placement agents
H.C. Wainwright & Co.
First sale
Feb 2021
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$550KraisedJun 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terrence W. NorchiExecutive Officer, Director
  • Richard E. DavisExecutive Officer
  • Punit DhillonDirector
  • James R. SulatDirector
Offering amount
$2M
Amount sold
$550K
First sale
Jun 2020
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedJun 2016 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Terrence W. NorchiExecutive Officer, Director
  • James R. SulatDirector
  • Avtar DhillonDirector
  • Richard E. DavisExecutive Officer
Offering amount
$3.5M
Amount sold
$3.4M
Sales commissions
$171K
Placement agents
MAXIM GROUP LLC
First sale
May 2016
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$750KraisedMar 2015 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William CotterExecutive Officer
  • Terrence NorchiExecutive Officer, Director
  • Richard DavisExecutive Officer
  • Avtar DhillonDirector
  • Arthur RosenthalDirector
Offering amount
$750K
Amount sold
$750K
First sale
Mar 2015
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.9MraisedFeb 2014 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Avtar DhillonDirector
  • William CotterExecutive Officer
  • Norchi TerrenceExecutive Officer, Director
  • Arthur RosenthalDirector
  • Alan BarberExecutive Officer
Offering amount
$2.9M
Amount sold
$2.9M
First sale
Feb 2014
Incorporated
Corporation, Nevada, 2009
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies working in the same space as Arch Therapeutics.

In the news

Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financingglobenewswire.com · Jul 2022Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Repriceglobenewswire.com · Jun 2020

Frequently asked questions

What does Arch Therapeutics do?
Arch Therapeutics develops the AC5 Advanced Wound System, a wound care product available in the USA for both government and non-government purchasers. The company operates in the medical device sector focused on wound management.
Who founded Arch Therapeutics?
Arch Therapeutics was founded by Terrence Norchi in 2009.
How much funding has Arch Therapeutics raised?
Arch Therapeutics has disclosed $18.7M raised across 6 rounds.
Where is Arch Therapeutics headquartered?
Arch Therapeutics is headquartered in Wellesley, US.